Akari Therapeutics enters strategic ADC payload research collaboration with Whitehawk TherapeuticsPUBT·Jul 22 at 07:40 AMWHWK0.00%AKTX-1.75%
Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology OpportunityGlobeNewswire·Jul 22 at 07:40 AMAKTX-1.75%WHWK0.00%
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics | AKTX Stock NewsStockTitan·Jul 20 at 10:05 PMAKTX-1.75%WHWK0.00%
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Sees Large Increase in Short InterestMarket Beat·Jul 14 at 05:40 AMWHWK0.00%BAC+0.36%
Biocytogen and Whitehawk partner to develop ADCsPharmaceutical Technology·Jul 8 at 02:59 AM02315+4.13%WHWK0.00%
Biocytogen, Whitehawk Therapeutics team up on bispecific antibody-drug conjugate developmentPUBT·Jul 7 at 07:07 AMWHWK0.00%02315+4.13%
Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026 | WHWK Stock NewsStockTitan·May 30 at 05:35 AMWHWK0.00%
